169 related articles for article (PubMed ID: 35462483)
1. [Study of the effects of long-term outcomes of autologous peripheral blood stem cell reinfusion in patients with decompensated cirrhosis].
Cui LN; Wang XF; Sun RQ; Deng J; Gao ZJ; Zhou XM; Guo CC; Jia G; Shang YL; Yang CM; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):279-284. PubMed ID: 35462483
[No Abstract] [Full Text] [Related]
2. Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis.
Guo C; Guo G; Zhou X; Chen Y; Han Z; Yang C; Zhao S; Su H; Lian Z; Leung PSC; Gershwin ME; Zhou X; Han Y
Clin Gastroenterol Hepatol; 2019 May; 17(6):1175-1182.e2. PubMed ID: 30613001
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal candidates for autologous peripheral blood stem cell therapy in patients with decompensated liver cirrhosis: a prognostic scoring system.
Tian S; Guo G; Zhou X; Liu Y; Jia G; Zheng L; Cui L; Wang K; Zhang M; Sun K; Ma S; Yang C; Zhou X; Guo C; Shang Y; Han Y
Stem Cell Res Ther; 2024 Jan; 15(1):8. PubMed ID: 38167085
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Follow-Up of Patients After Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis.
Kim JK; Kim SJ; Kim Y; Chung YE; Park YN; Kim HO; Kim JS; Park MS; Sakaida I; Kim DY; Lee JI; Ahn SH; Lee KS; Han KH
Cell Transplant; 2017 Jun; 26(6):1059-1066. PubMed ID: 28120743
[TBL] [Abstract][Full Text] [Related]
5. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
6. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
[TBL] [Abstract][Full Text] [Related]
7. A Clinic Study on Long-term Efficacy and Safety of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Decompensated Hepatitis B Cirrhosis.
Zhang X; Zheng D; He L; Li W; Zhou W; Pang Z; Huang J; Deng Q
Altern Ther Health Med; 2024 Jan; 30(1):160-166. PubMed ID: 37773668
[TBL] [Abstract][Full Text] [Related]
8. Autologous mobilized peripheral blood CD34(+) cell infusion in non-viral decompensated liver cirrhosis.
Sharma M; Rao PN; Sasikala M; Kuncharam MR; Reddy C; Gokak V; Raju B; Singh JR; Nag P; Nageshwar Reddy D
World J Gastroenterol; 2015 Jun; 21(23):7264-71. PubMed ID: 26109814
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of autologous stem cell transplantation for decompensated liver cirrhosis: A retrospective cohort study.
Wang MF; Li YB; Gao XJ; Zhang HY; Lin S; Zhu YY
World J Stem Cells; 2018 Oct; 10(10):138-145. PubMed ID: 30397424
[TBL] [Abstract][Full Text] [Related]
10. 3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy.
Lee CH; Kim IH; Moon JC; Seo SY; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Yang JD; Yu HC
World J Gastroenterol; 2017 Jan; 23(2):297-305. PubMed ID: 28127203
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
12. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
13. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis.
Mohamadnejad M; Alimoghaddam K; Bagheri M; Ashrafi M; Abdollahzadeh L; Akhlaghpoor S; Bashtar M; Ghavamzadeh A; Malekzadeh R
Liver Int; 2013 Nov; 33(10):1490-6. PubMed ID: 23763455
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis.
Mohamadnejad M; Alimoghaddam K; Mohyeddin-Bonab M; Bagheri M; Bashtar M; Ghanaati H; Baharvand H; Ghavamzadeh A; Malekzadeh R
Arch Iran Med; 2007 Oct; 10(4):459-66. PubMed ID: 17903050
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial.
Prajapati R; Arora A; Sharma P; Bansal N; Singla V; Kumar A
Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):448-455. PubMed ID: 27930386
[TBL] [Abstract][Full Text] [Related]
16. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
[TBL] [Abstract][Full Text] [Related]
17. Human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis (MSC-DLC-1): a dose-escalation, phase I trial protocol.
Wang Z; Li T; Zhang Z; Yuan M; Shi M; Wang FS; Linghu EQ; Shi L
BMJ Open; 2023 Dec; 13(12):e078362. PubMed ID: 38159943
[TBL] [Abstract][Full Text] [Related]
18. Multiple Cycles of Granulocyte Colony-Stimulating Factor Increase Survival Times of Patients With Decompensated Cirrhosis in a Randomized Trial.
De A; Kumari S; Singh A; Kaur A; Sharma R; Bhalla A; Sharma N; Kalra N; Singh V
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):375-383.e5. PubMed ID: 32088302
[TBL] [Abstract][Full Text] [Related]
19. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.
Kedarisetty CK; Anand L; Bhardwaj A; Bhadoria AS; Kumar G; Vyas AK; David P; Trehanpati N; Rastogi A; Bihari C; Maiwall R; Garg HK; Vashishtha C; Kumar M; Bhatia V; Sarin SK
Gastroenterology; 2015 Jun; 148(7):1362-70.e7. PubMed ID: 25749502
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis.
Bai YQ; Yang YX; Yang YG; Ding SZ; Jin FL; Cao MB; Zhang YR; Zhang BY
World J Gastroenterol; 2014 Jul; 20(26):8660-6. PubMed ID: 25024623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
